C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study
| Autor: | Ted A. W. Splinter, Loes E. Visser, André G. Uitterlinden, Claire Siemes, Jacqueline C. M. Witteman, Albert Hofman, Jan Willem Coebergh, Huibert A. P. Pols, Bruno H. Ch. Stricker |
|---|---|
| Přispěvatelé: | Pharmacy, Public Health, Internal Medicine, Epidemiology |
| Rok vydání: | 2006 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Lung Neoplasms Breast Neoplasms Gastroenterology Polymorphism Single Nucleotide Risk Assessment Prostate cancer Rotterdam Study SDG 3 - Good Health and Well-being Gene Frequency Risk Factors Internal medicine Neoplasms medicine Biomarkers Tumor Odds Ratio Humans Prospective Studies Risk factor Prospective cohort study Aged Netherlands Aged 80 and over Inflammation biology business.industry Hazard ratio C-reactive protein Cancer Genetic Variation Prostatic Neoplasms Odds ratio Middle Aged medicine.disease C-Reactive Protein Oncology Haplotypes Research Design Immunology Chronic Disease biology.protein Female business Colorectal Neoplasms |
| Zdroj: | Journal of Clinical Oncology, 24(33), 5216-5222. American Society of Clinical Oncology |
| ISSN: | 1527-7755 0732-183X |
| Popis: | Purpose It remains unclear if inflammation itself may induce cancer, if inflammation is a result of tumor growth, or a combination of both exists. The aim of this study was to examine whether C-reactive protein (CRP) levels and CRP gene variations were associated with an altered risk of colorectal, lung, breast, or prostate cancer. Patients and Methods A total of 7,017 participants age ≥ 55 years from the Rotterdam Study were eligible for analyses. Mean follow-up time was 10.2 years. High-sensitivity CRP measurements were performed to identify additional values of 0.2 to 1.0 mg/L compared with standard procedures. Genotypes of the CRP gene were determined with an allelic discrimination assay. Results High levels (> 3 mg/L) of CRP were associated with an increased risk of incident cancer (hazard ratio, 1.4; 95% CI, 1.1 to 1.7) compared with persons with low levels (< 1 mg/L), even after a potential latent period of 5 years was introduced. Although CRP seems to affect several cancer sites, the association was strongest for lung cancer (hazard ratio, 2.8; 95% CI, 1.6 to 4.9). A CRP single nucleotide polymorphism associated with decreased CRP levels was associated with an increased lung cancer risk of 2.6 (95% CI, 1.6 to 4.4) in homozygous carriers. Conclusion Baseline CRP levels seem to be a biomarker of chronic inflammation preceding lung cancer, even after subtracting a 5-year latent period. Furthermore, CRP gene variation associated with low CRP blood levels was relatively common in patients with lung cancer. Both chronic inflammation and impaired defense mechanisms resulting in chronic inflammation might explain these results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|